Capture100th

SPECTAcolor, the EORTC’s premier Screening Platform for Efficient Clinical Trial Access for patients with colorectal cancer, enrolled its 100th patient in February 2014.

“We are satisfied with the recruitment of patients with colorectal cancer and the analyses of their tumors. Chaussures Nike Pas Cher air max 1 pas cher Our efforts will lead to the creation of dedicated clinical trials in which targeted therapies will be tested on the basis of molecular biomarker analyses,” said Dr. Koop Fjallraven Kanken mochilas kanken baratas Gunnar Folprecht of Universitaetsklinikum Carl Gustav Carus, Dresden, Germany, one of the initiators and principal investigators of SPECTAcolor.

In practice, once the patient has consented to participate in SPECTAcolor, their biological material will be sent to the central pathology lab in Dresden, Germany, for molecular analysis. Nike Air Max 2016 Heren groen This will enable matching a given patient’s profile with suitable trials that are investigating targeted drugs.

The results of the analysis, that is the patient’s molecular profile, will be sent to the doctor treating that particular patient. Nike Air Max 2016 Heren wit Right from the start, this could help physicians make treatment choices.

The expected benefits from SPECTAcolor are many and range from a more structured approach for optimized patient access to clinical trials, new partnerships with the pharmaceutical industry, new opportunities for biomarker development with diagnostic companies, exploration of new forms of adaptive licensing with regulators and payers, and new opportunities for participating investigators to expand or develop new translational research projects according to their own particular subjects of interest.

Total number of enrolled patients per country as of 7 February 2014
Germany 65
Spain 18
Switzerland 20
Total 103

 

This encouraging start for SPECTAcolor is a tribute to the dedication of the many investigators at the institutions participating to this program. Cheap Nike Shoes Sale UK As of 07 February 2014, SPECTAcolor had opened in seven institutions in three countries, and additional sites, and in additional European countries, are expected to open soon.

Dr. Mochilas Kanken Baratas Carlo Messina, EORTC Clinical Research Physician, says, “SPECTAcolor is a pioneering clinical research model and promises to revolutionize the way we approach cancer treatment as a whole. Nike Air Max Pas Cher At the EORTC, we are not limiting this approach to colorectal cancer alone. comprar mochilas kanken chaussures nike tn requin Strategically, instead of testing a drug in all patients defined by the cancer site and subsequently defining responding subgroups, we hope to conduct studies in preselected subtypes of patients who express specific molecular characteristics and would more likely respond to a particular targeted agent.